

## Bölüm 15

# PARKİNSON HASTALIĞINDA MOTOR VE NONMOTOR SEMPTOMLAR

Şeyma EROĞLU DURMAZ<sup>1</sup>

### GİRİŞ

Parkinson Hastalığı (PH) Alzheimer tipi demanstan sonra ikinci en yaygın nörodejeneratif hastalıktır(1).Substansia Nigra(SN) pars compactada ki pigmentli dopaminerjik nöronların kronik ve progresif kaybı sonucu gelişir.PH'nin patolojik belirleyicisi  $\alpha$ -sinüklein proteinlerinin anormal katlanmalarından oluşan, nöronal inklüzyon cisimciği olan, Lewy cisimcikleridir(LC) (2).

İstirahat tremoru, rijidite, bradikinezi ve postüral instabilite gibi motor semptomlarla karakterize hipokinetik hareket bozukluğu olarak tanımlanır. Parkinsonizm vakalarının yaklaşık % 80'ini oluşturur (3).

Parkinson Hastalığı'nda bilişsel, psikiyatrik bozukluklar , disotonomi ve uyku bozukluklarını içeren non-motor semptomlar (NMS) hastalığın tüm seyri boyunca görülmektedir.

### PARKİNSON HASTALIĞINDA MOTOR SEMPTOMLAR

#### Tremor

En yaygın klinik belirtidir ve çoğunlukla ilk motor semptom olarak ortaya çıkar . Ancak PH' nin tanı ve takibi sırasında %15 oranında hastada hastalığın hiçbir döneminde gözlenmeyebilir (4).

Parkinson Hastalığı'nda tremor 4-6 Hz frekansında, istirahatte ve genellikle unilateral görülür, sıklıkla üst ekstremitelerde distalinden başlar. Fenomenolojik olarak küçük bir obje ya da hap yuvarlar gibi baş parmağı ve işaret parmağını içeren ritmik fleksiyon-ekstansiyon-opozisyon hareketleri ve el bileğinin pronasyon-supinasyon hareketleri ile karakterizedir.Mental aktivite, stres, diğer

<sup>1</sup> Uzm. Dr., Şanlıurfa Eğitim ve Araştırma Hastanesi, Nöroloji Kliniği,seymaerogludr@gmail.com

yayımlı sürecinde motor semptomlara eşlik eden ya da motor semptomların henüz görülmediği premotor dönemde başlayan nonmotor semptomlarda önemli yer tutmaktadır. Nonmotor semptomlar motor semptomlardan daha özürleyici olabilmektedir.

Parkinson Hastalığı'nın motor semptomlarından en sık görüleni tremor (asimetrik, istirahatte belirgin) olmakla beraber tanı için bradikinezi olmazsa olmaz kabul edilir. NMS'ler Nöropsikiyatrik semptomlar ve Nöropsikiyatrik olmayan semptomlar olarak sınıflandırılabilir. En sık görülen Nöropsikiyatrik NMS'lerdir.

Tedavide amaç hastanın bağımsızlık süresini uzatmak ve yaşam kalitesini artırmaktır, hastaya göre bireyselleştirilmelidir.

## KAYNAKLAR

1. Kalia LV, Lang AE. Parkinson's disease. *The Lancet*. Elsevier; 2015;386(9996): 896–912. doi:10.1016/S0140-6736(14)61393-3
2. Masters CL, Kril JJ, Halliday GM, et al. Overview and recent advances in neuropathology. Part 2: Neurodegeneration. *Pathology*. 2011;43(2): 93–102. doi:10.1097/PAT.0b013e3283426eee
3. Williams DR, Litvan I. Parkinsonian Syndromes. *Continuum: Lifelong Learning in Neurology*. 2013;19(5 Movement Disorders): 1189–1212. doi:10.1212/01.CON.0000436152.24038.e0
4. Benamer HT. Parkinsonism and tremor disorders. A clinical approach. *The Libyan Journal of Medicine*. 2007;2(2): 66–72. doi:10.4167/061222
5. Jankovic J. Parkinson's disease: clinical features and diagnosis. *Journal of Neurology, Neurosurgery & Psychiatry*. 2008;79(4): 368–376. doi:10.1136/jnnp.2007.131045
6. Jankovic J, Schwartz K, Ondo W. Re-emergent tremor of Parkinson's disease. *Journal of Neurology, Neurosurgery, and Psychiatry*. 1999;67(5): 646–650.
7. Deuschl G, Papengut F, Hellriegel H. The phenomenology of Parkinsonian tremor. *Parkinsonism & Related Disorders*. 2012;18: S87–S89. doi:10.1016/S1353-8020(11)70028-1
8. Hess CW, Okun MS. Diagnosing Parkinson Disease. *Continuum (Minneapolis, Minn.)*. 2016;22(4 Movement Disorders): 1047–1063. doi:10.1212/CON.0000000000000345
9. Distler M, Schlachetzki JC, Kohl Z, et al. Paradoxical kinesia in Parkinson's disease revisited: Anticipation of temporal constraints is critical. *Neuropsychologia*. 2016;86: 38–44. doi:10.1016/j.neuropsychologia.2016.04.012
10. Broussolle E, Krack P, Thobois S, et al. Contribution of Jules Froment to the study of Parkinsonian rigidity. *Movement Disorders*. 2007;22(7): 909–914. doi:10.1002/mds.21484

11. Kim YE, Jeon BS. Musculoskeletal problems in Parkinson's disease. *Journal of Neural Transmission*. 2013;120(4): 537–542. doi:10.1007/s00702-012-0960-2
12. Dickson DW. Parkinson's Disease and Parkinsonism: Neuropathology. *Cold Spring Harbor Perspectives in Medicine*. Cold Spring Harbor Laboratory Press; 2012;2(8): a009258. doi:10.1101/cshperspect.a009258
13. Pandey S, Garg H. Postural & striatal deformities in Parkinson's disease: Are these rare? *The Indian Journal of Medical Research*. 2016;143(1): 11–17. doi:10.4103/0971-5916.178577
14. Raza C, Anjum R, Shakeel N ul A. Parkinson's disease: Mechanisms, translational models and management strategies. *Life Sciences*. 2019;226: 77–90. doi:10.1016/j.lfs.2019.03.057
15. Nonnekes J, Goselink R, Weerdesteyn V, et al. The Retropulsion Test: A Good Evaluation of Postural Instability in Parkinson's Disease? *Journal of Parkinson's Disease*. 2015;5(1): 43–47. doi:10.3233/JPD-140514
16. Sveinbjornsdottir S. The clinical symptoms of Parkinson's disease. *Journal of Neurochemistry*. 2016;139(S1): 318–324. doi:10.1111/jnc.13691
17. Lord SR, Bindels H, Ketheeswaran M, et al. Freezing of Gait in People with Parkinson's Disease: Nature, Occurrence, and Risk Factors. *Journal of Parkinson's Disease*. 2020;10(2): 631–640. doi:10.3233/JPD-191813
18. Gao C, Liu J, Tan Y, et al. Freezing of gait in Parkinson's disease: pathophysiology, risk factors and treatments. *Translational Neurodegeneration*. 2020;9: 12. doi:10.1186/s40035-020-00191-5
19. Shin H-W, Hong S-W, Youn YC. Clinical Aspects of the Differential Diagnosis of Parkinson's Disease and Parkinsonism. *Journal of Clinical Neurology (Seoul, Korea)*. 2022;18(3): 259–270. doi:10.3988/jcn.2022.18.3.259
20. Sauerbier A, Jitkrisadakul O, Titova N, et al. Non-Motor Symptoms Assessed by Non-Motor Symptoms Questionnaire and Non-Motor Symptoms Scale in Parkinson's Disease in Selected Asian Populations. *Neuroepidemiology*. S. Karger AG; 2017;49(1–2): 1–18. doi:10.1159/000478702
21. Sauerbier A, Jenner P, Todorova A, et al. Non motor subtypes and Parkinson's disease. *Parkinsonism & Related Disorders*. 2016;22: S41–S46. doi:10.1016/j.parkrel-dis.2015.09.027
22. Chaudhuri KR, Martinez-Martin P. Quantitation of non-motor symptoms in Parkinson's disease. *European Journal of Neurology*. 2008;15: 2–8. doi:10.1111/j.1468-1331.2008.02212.x
23. Weintraub D, Aarsland D, Chaudhuri KR, et al. The neuropsychiatry of Parkinson's disease: advances and challenges. *The Lancet. Neurology*. 2022;21(1): 89–102. doi:10.1016/S1474-4422(21)00330-6
24. Schrag A, Taddei RN. Depression and Anxiety in Parkinson's Disease. *International Review of Neurobiology*. Elsevier; 2017. p. 623–655. doi:10.1016/bs.irn.2017.05.024
25. Getz SJ, Levin B. Cognitive and Neuropsychiatric Features of Early Parkinson's Disease. *Archives of Clinical Neuropsychology*. 2017;32(7): 769–785. doi:10.1093/arclin/acx091

26. Mele B, Van S, Holroyd-Leduc J, et al. Diagnosis, treatment and management of apathy in Parkinson's disease: a scoping review. *BMJ Open*. 2020;10(9): e037632. doi:10.1136/bmjopen-2020-037632
27. Aarsland D, Creese B, Politis M, et al. Cognitive decline in Parkinson disease. *Nature reviews. Neurology*. 2017;13(4): 217–231. doi:10.1038/nrneurol.2017.27
28. Rietdijk CD, Perez-Pardo P, Garssen J, et al. Exploring Braak's Hypothesis of Parkinson's Disease. *Frontiers in Neurology*. 2017;8: 37. doi:10.3389/fneur.2017.00037
29. Fasano A, Visanji NP, Liu LWC, et al. Gastrointestinal dysfunction in Parkinson's disease. *The Lancet Neurology*. 2015;14(6): 625–639. doi:10.1016/S1474-4422(15)00007-1
30. Adams-Carr KL, Bestwick JP, Shribman S, et al. Constipation preceding Parkinson's disease: a systematic review and meta-analysis. *Journal of Neurology, Neurosurgery & Psychiatry*. 2016;87(7): 710–716. doi:10.1136/jnnp-2015-311680
31. Wakabayashi K, Tanji K, Odagiri S, et al. The Lewy Body in Parkinson's Disease and Related Neurodegenerative Disorders. *Molecular Neurobiology*. 2013;47(2): 495–508. doi:10.1007/s12035-012-8280-y
32. Palma J-A, Norcliffe-Kaufmann L, Kaufmann H. Diagnosis of multiple system atrophy. *Autonomic neuroscience : basic & clinical*. 2018;211: 15–25. doi:10.1016/j.autneu.2017.10.007
33. Coon EA, Low PA. Thermoregulation in Parkinson disease. *Handbook of Clinical Neurology*. Elsevier; 2018. p. 715–725. doi:10.1016/B978-0-444-64074-1.00043-4
34. Shah P, Sagar PR, Alhumaidi N, et al. Parkinson's Disease and Its Dermatological Associations: Is Your Skin Whispering You a Diagnosis? *Cureus*. 12(8): e9933. doi:10.7759/cureus.9933
35. Chen Z, Li G, Liu J. Autonomic dysfunction in Parkinson's disease: Implications for pathophysiology, diagnosis, and treatment. *Neurobiology of Disease*. 2020;134: 104700. doi:10.1016/j.nbd.2019.104700
36. Yeo L, Singh R, Gundeti M, et al. Urinary tract dysfunction in Parkinson's disease: a review. *International Urology and Nephrology*. 2012;44(2): 415–424. doi:10.1007/s11255-011-9969-y
37. Sakushima K, Yamazaki S, Fukuma S, et al. Influence of urinary urgency and other urinary disturbances on falls in Parkinson's disease. *Journal of the Neurological Sciences*. 2016;360: 153–157. doi:10.1016/j.jns.2015.11.055
38. Balami J, Robertson D. Parkinson's disease and sexuality. *British Journal of Hospital Medicine*. 2007;68(12): 644–647. doi:10.12968/hmed.2007.68.12.644
39. Weintraub D, Mamikonyan E. Impulse Control Disorders in Parkinson's Disease. *American Journal of Psychiatry*. 2019;176(1): 5–11. doi:10.1176/appi.ajp.2018.18040465
40. Stefani A, Högl B. Sleep in Parkinson's disease. *Neuropsychopharmacology*. 2020;45(1): 121–128. doi:10.1038/s41386-019-0448-y
41. Loddo G, Calandra-Buonaura G, Sambati L, et al. The Treatment of Sleep Disorders in Parkinson's Disease: From Research to Clinical Practice. *Frontiers in Neurology*. 2017;8: 42. doi:10.3389/fneur.2017.00042
42. Dauvilliers Y, Schenck CH, Postuma RB, et al. REM sleep behaviour disorder. *Nature Reviews. Disease Primers*. 2018;4(1): 19. doi:10.1038/s41572-018-0016-5

43. St Louis EK, Boeve AR, Boeve BF. REMSleep Behavior Disorder in Parkinson's Disease and Other Synucleinopathies: REM Sleep Behavior Disorder in Synucleinopathies. *Movement Disorders*. 2017;32(5): 645–658. doi:10.1002/mds.27018
44. Zhang Y, Ren R, Sanford LD, et al. Sleep in Parkinson's disease: A systematic review and meta-analysis of polysomnographic findings. *Sleep Medicine Reviews*. 2020;51: 101281. doi:10.1016/j.smrv.2020.101281
45. Möller JC, Unger M, Stiasny-Kolster K, et al. Restless Legs Syndrome (RLS) and Parkinson's disease (PD)—Related disorders or different entities? *Journal of the Neurological Sciences*. 2010;289(1–2): 135–137. doi:10.1016/j.jns.2009.08.035
46. Sateia MJ. International Classification of Sleep Disorders-Third Edition. *Chest*. 2014;146(5): 1387–1394. doi:10.1378/chest.14-0970
47. Yeung EYH, Cavanna AE. Sleep Attacks in Patients With Parkinson's Disease on Dopaminergic Medications: A Systematic Review. *Movement Disorders Clinical Practice*. 2014;1(4): 307–316. doi:10.1002/mdc3.12063
48. Blanchet PJ, Brefel-Courbon C. Chronic pain and pain processing in Parkinson's disease. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 2018;87: 200–206. doi:10.1016/j.pnpbp.2017.10.010
49. Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson's disease: Frequent and disabling. *Neurology*. 2002;59(3): 408–413. doi:10.1212/WNL.59.3.408
50. Hawkes CH, Del Tredici K, Braak H. Parkinson's Disease: The Dual Hit Theory Revisited. *Annals of the New York Academy of Sciences*. 2009;1170(1): 615–622. doi:10.1111/j.1749-6632.2009.04365.x
51. Savitt J, Aouchiche R. Management of Visual Dysfunction in Patients with Parkinson's Disease. *Journal of Parkinson's Disease*. 10(Suppl 1): S49–S56. doi:10.3233/JPD-202103
52. Siciliano M, Trojano L, Santangelo G, et al. Fatigue in Parkinson's disease: A systematic review and meta-analysis: Fatigue in Parkinson's Disease. *Movement Disorders*. 2018;33(11): 1712–1723. doi:10.1002/mds.27461
53. Reichmann H. Premotor Diagnosis of Parkinson's Disease. *Neuroscience Bulletin*. 2017;33(5): 526–534. doi:10.1007/s12264-017-0159-5
54. Noyce AJ, Bestwick JP, Silveira-Moriyama L, et al. Meta-Analysis of Early Nonmotor Features and Risk Factors for Parkinson Disease. *Annals of Neurology*. 2012;72(6): 893–901. doi:10.1002/ana.23687